- Home
- SMBK vs IMTX Comparison
SMBK vs IMTX Comparison
Compare SMBK & IMTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SMBK
- IMTX
- Stock Information
- Founded
- SMBK N/A
- IMTX 2000
- Country
- SMBK United States
- IMTX Germany
- Employees
- SMBK N/A
- IMTX N/A
- Industry
- SMBK Major Banks
- IMTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SMBK Finance
- IMTX Health Care
- Exchange
- SMBK Nasdaq
- IMTX Nasdaq
- Market Cap
- SMBK 602.3M
- IMTX 653.9M
- IPO Year
- SMBK N/A
- IMTX N/A
- Fundamental
- Price
- SMBK $36.84
- IMTX $5.88
- Analyst Decision
- SMBK Buy
- IMTX Strong Buy
- Analyst Count
- SMBK 4
- IMTX 4
- Target Price
- SMBK $37.25
- IMTX $14.67
- AVG Volume (30 Days)
- SMBK 47.3K
- IMTX 840.5K
- Earning Date
- SMBK 10-20-2025
- IMTX 08-13-2025
- Dividend Yield
- SMBK 0.87%
- IMTX N/A
- EPS Growth
- SMBK 62.51
- IMTX N/A
- EPS
- SMBK 2.47
- IMTX N/A
- Revenue
- SMBK $178,959,000.00
- IMTX $152,823,253.00
- Revenue This Year
- SMBK $22.86
- IMTX N/A
- Revenue Next Year
- SMBK $10.59
- IMTX N/A
- P/E Ratio
- SMBK $14.93
- IMTX N/A
- Revenue Growth
- SMBK 20.51
- IMTX 83.61
- 52 Week Low
- SMBK $26.31
- IMTX $3.30
- 52 Week High
- SMBK $37.72
- IMTX $13.09
- Technical
- Relative Strength Index (RSI)
- SMBK 55.94
- IMTX 53.09
- Support Level
- SMBK $36.52
- IMTX $5.68
- Resistance Level
- SMBK $37.60
- IMTX $6.01
- Average True Range (ATR)
- SMBK 0.63
- IMTX 0.33
- MACD
- SMBK -0.04
- IMTX 0.07
- Stochastic Oscillator
- SMBK 39.29
- IMTX 74.18
About SMBK SmartFinancial Inc.
SmartFinancial Inc operates as a bank holding company for SmartBank. It offers various banking and financial services to individuals and corporate customers. The principal business of the Bank consists of attracting deposits from the general public and investing those funds, together with funds generated from operations and from principal and interest payments on loans, mainly in commercial loans, commercial and residential real estate loans, consumer loans, and residential and commercial construction loans. The primary source of revenue is interest income from earning assets, namely loans and securities.
About IMTX Immatics N.V.
Immatics NV is a biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.